- Home
- TRMD vs ATAI Comparison
TRMD vs ATAI Comparison
Compare TRMD & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRMD | ATAI |
|---|---|---|
| Founded | 1889 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2016 | 2025 |
Fundamental Metrics
Financial Performance| Metric | TRMD | ATAI |
|---|---|---|
| Price | $31.61 | $7.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $35.00 | $15.88 |
| AVG Volume (30 Days) | 445.3K | ★ 8.6M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $19.30 | $3.27 |
| 52 Week High | $35.33 | $7.45 |
Technical Indicators
Market Signals| Indicator | TRMD | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 63.49 | 72.67 |
| Support Level | $31.08 | $3.89 |
| Resistance Level | $31.76 | N/A |
| Average True Range (ATR) | 0.64 | 0.05 |
| MACD | 0.22 | -0.07 |
| Stochastic Oscillator | 78.54 | 68.52 |
Price Performance
Historical ComparisonAbout TRMD TORM plc
TORM PLC operates as a shipping company mainly owning and operating a fleet of product tankers. It is engaged in the transportation of refined oil products and clean petroleum products, including gasoline, jet fuel, naphtha, and diesel oil. The Company operates through two segments: the Tanker segment and the Marine Engineering segment, deriving the majority of its revenue from the Tanker segment.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.